Bank Julius Baer & Co. Ltd Zurich Decreases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Bank Julius Baer & Co. Ltd Zurich trimmed its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 18.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,232 shares of the biotechnology company’s stock after selling 11,028 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.18% of Arcturus Therapeutics worth $1,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. New York State Teachers Retirement System bought a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at approximately $53,000. China Universal Asset Management Co. Ltd. increased its position in shares of Arcturus Therapeutics by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,406 shares during the last quarter. Arizona State Retirement System bought a new position in shares of Arcturus Therapeutics during the 4th quarter valued at approximately $211,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Arcturus Therapeutics by 5.9% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock valued at $277,000 after purchasing an additional 606 shares during the last quarter. Finally, Stratos Wealth Partners LTD. bought a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at approximately $301,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Trading Up 1.5 %

Shares of ARCT stock opened at $26.55 on Friday. Arcturus Therapeutics Holdings Inc. has a twelve month low of $17.52 and a twelve month high of $43.81. The stock has a fifty day simple moving average of $33.73 and a two-hundred day simple moving average of $29.80.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The business had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $64.14 million. Equities research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ARCT has been the topic of several analyst reports. Citigroup boosted their target price on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a research report on Friday, March 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $61.33.

Insiders Place Their Bets

In other Arcturus Therapeutics news, COO Pad Chivukula sold 8,565 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $35.01, for a total value of $299,860.65. Following the completion of the sale, the chief operating officer now directly owns 490,883 shares in the company, valued at approximately $17,185,813.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.